This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-18 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
So, the term "Satsuma ware" came to be associated not with a place of origin but with lower-quality ware created purely for export. Despite this, artists such as Yabu Meizan and Makuzu Kōzan maintained the highest artistic standards while also successfully exporting. From 1876 to 1913, Kōzan won prizes at 51 exhibitions, including the World's fair and the National Industrial Exhibition.
Cy1: Curly; the wings curve away from the body, flight may be somewhat impaired e1: Ebony; black body and wings (heterozygotes are also visibly darker than wild type) Sb1: Stubble; bristles are shorter and thicker than wild type w1: White; eyes lack pigmentation and appear white bw: Brown; eye color determined by various pigments combined. y1: Yellow; body pigmentation and wings appear yellow, the fly analog of albinism
== Mechanism == The substrates for the peptidyl transferase reaction are two tRNA molecules: one in the peptidyl site, bearing the growing peptide chain, and the other in the aminoacyl site, bearing the amino acid that will be added to the chain. The peptidyl chain and the incoming amino acid are attached to their respective tRNAs via ester bonds to the oxygen atom at the 3' ends of these tRNAs. The 3' ends of all tRNAs share a universally conserved CCA sequence. The alignment between the CCA ends of the ribosome-bound peptidyl tRNA and aminoacyl tRNA in the peptidyl transferase center contribute to peptide bond formation by providing the proper orientation for the reaction to occur. This reaction occurs via nucleophilic displacement. The amino group of the aminoacyl tRNA attacks the terminal carbonyl group of the peptidyl tRNA. The reaction proceeds through a tetrahedral intermediate and the loss of the P site tRNA as a leaving group. In peptidyl-tRNA hydrolysis, the same mechanism is used, but with a water molecule as the nucleophile.
In mid-December 2009, Sanders successfully added a provision to the Affordable Care Act to fund $11 billion to community health centers, especially those in rural areas. The provision brought together Democrats on the left with Democrats from conservative, rural areas, helping to secure the 60 votes needed for passage. On May 4, 2017, in response to the House vote to repeal and replace the Affordable Care Act, he predicted "thousands of Americans would die" from no longer having access to health care. PolitiFact rated his statement "mostly true". In September 2017, Sanders along with 15 Senate co-sponsors submitted the Medicare for All bill, a single-payer healthcare plan. The bill covers vision and dental care, unlike Medicare. Some Republicans have called the bill "Berniecare" and "the latest Democratic push for socialized medicine and higher taxes." He responded that the Republican Party has no credibility on the issue of health care after voting for legislation that would take health insurance away from 32 million Americans under the Affordable Care Act. As chairman of the Senate Subcommittee on Primary Health and Aging, Sanders introduced legislation in 2013 to reauthorize and strengthen the Older Americans Act, which supports Meals on Wheels and other programs for seniors.
Sources: en.wikipedia.org
Arby's promoted their announcement by breaking two Guinness World Records. The first record, "world's smallest advertisement", measured 38.3 microns by 19.2 microns on a sesame seed and was printed at Georgia Tech. The second record, "largest advertising poster", took up approximately 5 acres of land and was placed in Monowi, Nebraska, America's smallest town. Toasted Subs, sandwiches served on a toasted ciabatta roll, were first introduced in September 2007. The initial line-up included the French Dip & Swiss Toasted Sub, Philly Beef Toasted Sub, Classic Italian Toasted Sub, and Turkey Bacon Club. Three months later, the Toasted Subs product line was extended to include the Meatball Toasted Sub and the Chicken Parmesan Toasted Sub. In October 2013, Arby's introduced a Smokehouse Brisket sandwich. In September 2014, Arby's introduced gyros to its menu for a limited time. Gyros were previously offered in 2006. They have since become a permanent menu fixture on the menu in April 2016. On an almost annual basis, Arby's had offered some sort of a flatbread melt sandwich for a limited time. In 2007 and again in 2008, it was the Philly Cheesesteak and the Fajita Beef. The Beef Fajita returned with the new Chicken Fajita in 2009. After a six-year hiatus, Steak Fajita Flatbreads were offered for a limited time in 2015. The following year, Steak Fajita returned in 2016 with Chicken Fajita along with a choice between a hot and mild sauce. After a nine-year hiatus, a pork-beef mixture meatball sandwich was reintroduced in July 2016.
=== Mechanism of action === Opicapone blocks the enzyme catechol-O-methyltransferase (COMT) effectively (>90% at therapeutic doses), selectively and reversibly, and only outside the central nervous system. It dissociates slowly from COMT, resulting in a duration of action longer than 24 hours despite its short blood plasma half-life. As COMT and DOPA decarboxylase are the main enzymes for degrading levodopa, blocking the two effectively increases its concentrations in the bloodstream. More levodopa reaches the brain, where it is activated to dopamine.
The society publishes three research journals and a review journal: the Journal of Pharmacology and Experimental Therapeutics, Drug Metabolism and Disposition, Molecular Pharmacology, and Pharmacological Reviews Starting in 2012 these publications are only offered online. The society copublishes a wholly open access journal with the British Pharmacological Society and Wiley entitled Pharmacology Research & Perspectives. ASPET also publishes a quarterly newsletter, The Pharmacologist, and, from 2001 to 2011, Molecular Interventions magazine. The society gives out several awards:
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.